Year-to-year trajectories of hospital utilisation rates among patients with COPD: a retrospective cohort study

Demession	
Demographics	Age
	Sex
	Ethnicity
	Height
	Weight
Comorbidities	All comorbidities including, but not limited to:
	Myocardial infarction
	Congestive heart failure
	Peripheral vascular disease
	Cerebrovascular disease
	Hemiplegia or paraplegia
	Dementia
	Chronic pulmonary disease
	Rheumatologic disease
	Peptic ulcer disease
	Diabetes (with or without complications)
	Renal disease
	Malignancy
	Metastatic solid tumour
	Liver disease (mild, moderate or severe)
	Acquired immune deficiency syndrome
	Hypertension
	Dyslipidaemia
	Asthma
	Gastroesophageal reflux disease
	Depression
	Anxiety
COPD classification (grading or	FEV ₁
ABCD grouping)	CAT score
	Exacerbations leading to hospitalisation
Smoking status	Ex-smoker
	Current smoker
	Never-smoker

Supplemental table S1 Variables included in the CGH COPD database warehouse

1

Variable	Description	
	Pack-year history	
Vaccines	Pneumococcal (PCV13 or PPSV23) vaccinations	
	Influenza vaccinations	
Investigations	Laboratory results, including full blood count (eg,	
	eosinophils), C-reactive protein, procalcitonin and arterial	
	blood gases	
	Microbiology results, including sputum gram stain and	
	culture, tuberculosis smear and culture	
	Lung function tests, including pre- and post-bronchodilator	
	spirometry (FEV1/FVC ratio), diffusion capacity, lung	
	volumes, 6-minute walk test, exhaled nitric oxide test	
	Radiology, including chest x-ray and computed	
	tomography	
	2D echocardiography, including left ventricular ejection	
	fraction and pulmonary hypertension echocardiography	
Patient-reported outcomes	CAT score	
Medications (only within CGH)	Quantity of medications prescribed and quantity of	
	medications dispensed within CGH	
	All medications including, but not limited to (including	
	combinations of):	
	SABA	
	SAMA	
	LABA	
	LAMA	
	ICS	
	Methylxanthine (eg, theophylline)	
	Phosphodiesterase type 4 inhibitor (eg, roflumilast)	
	Antibiotics (eg, penicillins, fluoroquinolones, macrolides,	
	tetracycline)	
	Beta-blockers	
	Diuretics	
	Antiplatelets and angiotensin-converting enzyme inhibitors	
Mortality	Date of death	
Hospital encounters, including dates	ED visits	
and times	All-cause and COPD-related admissions	
	Mechanical ventilation (invasive and non-invasive)	
	Diagnostic codes	
	Outpatient visits	
Hospital encounters, including dates	LAMAICSMethylxanthine (eg, theophylline)Phosphodiesterase type 4 inhibitor (eg, roflumilast)Antibiotics (eg, penicillins, fluoroquinolones, macrolidestetracycline)Beta-blockersDiureticsAntiplatelets and angiotensin-converting enzyme inhibitionDate of deathED visitsAll-cause and COPD-related admissionsMechanical ventilation (invasive and non-invasive)Diagnostic codes	

.

Description			
Severity of exacerbation (ICU/mechanical ventilation or			
not)			
ent Test; CGH, Changi General Hospital; COPD, chronic			
obstructive pulmonary disease; ED, emergency department; FEV1, forced expiratory volume in 1 second;			
$\label{eq:FVC} FVC, forced \ vital \ capacity; \ ICS, \ inhaled \ corticosteroid; \ ICU, \ intensive \ care \ unit; \ LABA, \ long-acting \ \beta_2-agonist;$			
LAMA, long-acting muscarinic antagonist; SABA, short-acting β_2 -agonist; SAMA, short-acting muscarinic			

Supplemental table S2 Patient baseline characteristics

		Analysis of COPD-related	Analysis of all-cause
	Total (N=396)	hospitalisations/ED visits (n=394)	hospitalisations/ED visits (n=389)
Age, years, median (IQR)	70 (60–79)	70 (61–79)	70 (61–79)
Male, n (%)	346 (87.4)	344 (87.3)	339 (87.1)
Ethnicity, n (%)			
Chinese	218 (55.1)	218 (55.3)	215 (55.3)
Malay	95 (24.0)	94 (23.9)	92 (23.7)
Indian	36 (9.1)	36 (9.1)	36 (9.3)
Other	47 (11.9)	46 (11.7)	46 (11.8)
Smoking history, n (%)			
Current smoker	162 (40.9)	161 (40.9)	158 (40.6)
Ex-smoker	159 (40.2)	158 (40.1)	156 (40.1)
Never-smoker	40 (10.1)	40 (10.2)	40 (10.3)
Unknown	35 (8.8)	35 (8.8)	35 (9.0)
Body mass index, kg/m ²			
Median (IQR)	23.4 (19.5–27.4)	23.4 (19.5–27.3)	23.4 (19.5–27.4)
Unknown, n (%)	141 (36.2)	142 (36.0)	141 (36.2)
CAT score			
Median (IQR)	14 (9–19)	14 (9–19)	14 (9–20)
Unknown, n (%)	258 (65.4)	258 (65.4)	255 (65.6)
Lung function test, median (IQR)			
Post-bronchodilator FEV1 (L)	1.52 (1.12–2.00)	1.53 (1.12–2.00)	1.53 (1.12–2.01)
Post-bronchodilator FEV1% predicted	70 (54–84)	70 (54–84)	70 (55–84)
GOLD grade, n (%)			

GOLD grade 1 (≥80%)

GOLD grade 2 (50-79%)

GOLD grade 3 (30-49%)

Blood eosinophil count (cells/µl), median (IQR)

Elixhauser comorbidity score, median (IQR)

GOLD grade 4 (<30%)

Unknown

Median (IQR)

Unknown, n (%)

Comorbidities, n (%) Hypertension

> Hyperlipidaemia Diabetes

Asthma Heart failure

year 1

Bronchiectasis

Anxiety/depression

Obstructive sleep apnoea

Pulmonary tuberculosis

Stroke/transient ischaemic attack

Moderate-to-severe COPD exacerbations in

Ischaemic heart disease

Chronic kidney disease

Atrial fibrillation/arrhythmias

86 (21.8)

152 (38.6)

53 (13.5)

100 (25.3)

76 (19.3)

200 (100-400)

3 (0.8)

86 (21.7)

153 (38.6)

100 (25.3)

77 (19.4)

200 (100-400)

3 (13.6)

3 (0.8)

8 (3–17)	8 (3–17)	8 (3–18)
201 (50.8)	200 (50.8)	196 (50.4)
163 (41.2)	162 (41.1)	159 (40.9)
135 (34.1)	135 (34.3)	132 (33.9)
129 (32.6)	129 (32.7)	126 (32.4)
80 (20.2)	80 (20.3)	78 (20.1)
77 (19.4)	76 (19.3)	75 (19.3)
73 (18.4)	71 (18.0)	71 (18.3)
64 (16.2)	64 (16.2)	63 (16.2)
32 (8.1)	31 (7.9)	30 (7.7)
26 (6.6)	24 (6.1)	15 (3.9)
23 (5.8)	23 (5.8)	23 (5.9)
3 (0.8)	3 (0.8)	3 (0.8)
2 (0.5)	2 (0.5)	2 (0.5)
		-

85 (21.9)

152 (39.1)

52 (13.4)

99 (25.4)

76 (19.3)

200 (100-400)

1 (0.3)

5

Average, per person per year	0.99	0.88	0.86
Median (IQR)	0 (0–1)	0 (0–1)	0 (0–1)
All-cause hospitalizations/ED visits during			
baseline			
Average, per person per year	3.07	2.94	2.71
Median (IQR)	2 (1–4)	2 (1–4)	2 (1–4)

CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; ED, emergency department; FEV₁, forced expiratory volume in 1 second; GOLD, Global Initiative for

Chronic Obstructive Lung Disease; IQR, interquartile range.

Supplemental table S3 Patient baseline characteristics of excluded patients

		Patients who were excluded due to
	Patients who died	zero visits in any
	during the study	one of the study
	period	years
	(n=475)	(n=735)
Age, years, median (IQR)	78 (70–84)	70 (62–79)
Male, n (%)	425 (89.5)	644 (87.6)
Ethnicity, n (%)		
Chinese	329 (69.3)	432 (58.8)
Malay	85 (17.9)	166 (22.6)
Indian	25 (5.3)	57 (7.8)
Other	36 (7.5)	80 (10.8)
Smoking history, n (%)		
Current smoker	138 (29.1)	266 (36.2)
Ex-smoker	224 (47.2)	260 (35.4)
Never-smoker	28 (5.9)	44 (6.0)
Unknown	85 (17.8)	165 (22.4)
Body mass index, kg/m ²		
Median (IQR)	20.1 (17.4–24.2)	22.2 (19.1–25.6)
Unknown, n (%)	224 (47.1)	457 (62.2)
CAT score		
Median (IQR)	16 (11–20)	12 (8–16)
Unknown, n (%)	335 (70.5)	593 (80.6)
Lung function test, median (IQR)		
Post-bronchodilator FEV1 (L)	1.29 (0.96–1.73)	1.53 (1.15–1.99)
Post-bronchodilator FEV1% predicted	64 (48–84)	72 (56–88)
GOLD grade, n (%)		
GOLD grade 1 (≥80%)	66 (13.9)	158 (21.5)
GOLD grade 2 (50–79%)	100 (21.1)	171 (23.3)
GOLD grade 3 (30-49%)	53 (11.2)	59 (8.0)
GOLD grade 4 (<30%)	11 (2.3)	10 (1.4)
Unknown	245 (51.6)	337 (45.9)
Blood eosinophil count (cells/µl), median (IQR)		
Median (IQR)	100 (0–237)	150 (5–325)
Unknown, n (%)	131 (27.6)	386 (52.5)
Elixhauser comorbidity score, median (IQR)	14 (8–24)	3 (3–9)

	Patients who died	Patients who were excluded due to zero visits in any
		-
	during the study period	one of the study years
	(n=475)	(n=735)
Comorbidities, n (%)	()	(
Hypertension	233 (50.9)	236 (32.1)
Ischaemic heart disease	217 (45.7)	165 (22.4)
Hyperlipidaemia	114 (24.0)	136 (18.5)
Diabetes	130 (27.4)	136 (18.5)
Chronic kidney disease	130 (27.4)	77 (10.5)
Atrial fibrillation/arrhythmias	112 (23.6)	66 (9.0)
Asthma	15 (3.2)	68 (9.3)
Heart failure	122 (25.7)	77 (10.5)
Bronchiectasis	38 (8.0)	30 (4.1)
Anxiety/depression	28 (5.9)	13 (1.8)
Obstructive sleep apnoea	7 (1.5)	10 (1.4)
Stroke/transient ischaemic attack	1 (0.2)	3 (0.4)
Pulmonary tuberculosis	11 (2.3)	11 (1.5)
Noderate-to-severe COPD exacerbations in	year 1	
Average, per person	0.88	0.40
Median (IQR)	0 (0–1)	0 (0–1)
All-cause hospitalisation/ED visits during bas	seline	
Average, per person	2.52	1.14
Median (IQR)	1 (1–3)	1 (0–2)

FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease;


IQR, interquartile range.

Supplemental figure S1 Study design.

1 October 2017 to 30 September 2018	1 October 2018 to 30 September 2019 ► <	1 October 2019 to 30 September 2020 ► ◀
Year 1 (baseline)	Year 2	Year 3
۲ Baseline variables		
	۲ Outcome variables	


Supplemental figure S2 Patient disposition. CGH, Changi General Hospital;

COPD, chronic obstructive pulmonary disease; ED, emergency department.




Supplemental figure S3 Association between GOLD grade and likely trajectory.

GOLD, Global Initiative for Chronic Obstructive Lung Disease.





BMJ Open

Supplemental figure S4 (A–D) Treatment regimen by trajectory for COPD-related hospitalisations/ED visits. 'Others' includes ICS monotherapy, ICS with SABA and ICS with LAMA. COPD, chronic obstructive pulmonary disease; ED, emergency department; ICS, inhaled corticosteroid; LABA, long-acting β_2 -agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β_2 -agonist; SAMA, short-acting muscarinic antagonist.



B) Trajectory C2 (n=54)





D) Trajectory C4 (n=20)

